FilingReader Intelligence
Henlius' ophthalmic drug application accepted by NMPA
August 13, 2025 at 09:11 AM UTC•By FilingReader AI
Shanghai Henlius Biotech's new drug application for HLX04-O, treating wet age-related macular degeneration, has been accepted by China's NMPA.
The application is backed by Phase 3 trials showing the treatment matched ranibizumab's effectiveness. China's wet age-related macular degeneration market was worth approximately 4.90bn yuan in 2024.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:2696•Hong Kong Exchange
News Alerts
Get instant email alerts when Shanghai Henlius Biotech, Inc publishes news
Free account required • Unsubscribe anytime